AOD-9604 and Cartilage: The Unexpected Joint Finding

AOD-9604

Group 4 Lowest OA Scores

In a rabbit osteoarthritis model, combined AOD-9604 and hyaluronic acid injections produced the lowest cartilage degeneration scores of any treatment group.

Kwon & Park, Annals of Clinical and Laboratory Science, 2015

Kwon & Park, Annals of Clinical and Laboratory Science, 2015

View as image

A peptide built to burn fat ended up showing cartilage-protective properties in animal models. AOD-9604, the synthetic C-terminal fragment of human growth hormone spanning amino acids 176 to 191, was developed by Metabolic Pharmaceuticals in Australia during the 1990s as an anti-obesity drug.^[1] After its obesity program was terminated in 2007 following a failed Phase IIb trial, researchers noticed something unexpected: the peptide appeared to stimulate proteoglycan and collagen synthesis in cartilage cells. This finding redirected AOD-9604 research toward joint health, producing a small but interesting body of preclinical evidence. For a full overview of this peptide, including its development history and metabolic research, see our AOD-9604 guide.

The cartilage research remains limited. One published animal study, a handful of in vitro observations, and no human clinical trials with cartilage endpoints constitute the entire evidence base. That gap between preclinical promise and clinical validation is the central story of AOD-9604 and cartilage.

How a Fat-Loss Peptide Became a Cartilage Candidate

AOD-9604's original purpose had nothing to do with joints. Ng and colleagues at Monash University synthesized it as a 16-amino-acid fragment of human growth hormone (hGH), hypothesizing that the C-terminal region of hGH carried the molecule's fat-burning activity independently of its growth-promoting effects.^[2] That hypothesis proved partially correct. In obese Zucker rats, 19 days of oral AOD-9604 at 500 mcg/kg reduced body weight gain by over 50% compared to controls, and the treatment did not impair insulin sensitivity, unlike full-length growth hormone.^[2]

Heffernan and colleagues confirmed in 2001 that AOD-9604 reduces body weight and increases fat oxidation in obese mice, but critically demonstrated that it does not bind the human growth hormone receptor and does not stimulate cell proliferation through that receptor.^[3] This distinction matters for cartilage research because growth hormone's effects on joint tissue are mediated through different pathways than its metabolic effects. A separate study by the same group showed AOD-9604's lipolytic effects involve upregulation of beta-3 adrenergic receptors, a mechanism entirely unrelated to cartilage biology.^[4]

The connection to cartilage emerged from observations that growth hormone itself has well-documented effects on chondrocytes (cartilage cells), and researchers began asking whether the C-terminal fragment retained any of those properties through a receptor-independent mechanism.

The Rabbit Osteoarthritis Study: The Only Published Animal Trial

The single most cited piece of evidence for AOD-9604's cartilage effects comes from Kwon and Park, published in the Annals of Clinical and Laboratory Science in 2015.^[5] This study is worth examining in detail because it is, to date, the only published controlled animal trial evaluating AOD-9604 for a joint endpoint.

Study design: Thirty-two mature New Zealand white rabbits received bilateral knee injections of 2 mg collagenase type II to induce osteoarthritis. The rabbits were then divided into four groups receiving weekly ultrasound-guided intra-articular injections:

• Group 1: 0.6 mL saline (control)
• Group 2: 6 mg hyaluronic acid (HA)
• Group 3: 0.25 mg AOD-9604
• Group 4: 0.25 mg AOD-9604 combined with 6 mg HA

Injections continued for 4 to 7 weeks after the first collagenase injection. At 8 weeks, the researchers assessed cartilage degeneration using gross morphological scoring and histopathological analysis, and recorded the duration of lameness in each group.

Results: Mean gross morphological and histopathological scores were highest (worst) in the saline control group and lowest (best) in the combination AOD-9604 plus HA group. The combination group showed statistically lower degeneration scores than either HA alone or AOD-9604 alone. The lameness period in Group 4 was shorter than all other groups.^[5]

What this means: In this specific model, AOD-9604 enhanced cartilage outcomes, and the combination with hyaluronic acid outperformed either treatment individually. The authors concluded that intra-articular AOD-9604 injections "enhanced cartilage regeneration" in the collagenase-induced OA model.

What this does not mean: A single rabbit study with 32 animals, using a chemically induced arthritis model, cannot establish clinical efficacy. Collagenase-induced OA in rabbits does not perfectly replicate the chronic, multifactorial nature of human osteoarthritis. The study did not measure molecular markers of cartilage metabolism, did not assess long-term outcomes beyond 8 weeks, and did not evaluate systemic safety parameters. These are standard limitations of early-stage preclinical research, not unique flaws of this particular study.

The In Vitro Evidence: Proteoglycan and Collagen Synthesis

Beyond the rabbit trial, the cartilage case for AOD-9604 rests on in vitro observations. Researchers have reported that AOD-9604 exposure stimulates proteoglycan and collagen synthesis in chondrocyte cultures. Proteoglycans (particularly aggrecan) and type II collagen are the two main structural macromolecules in articular cartilage. Their degradation is a hallmark of osteoarthritis progression.

In joint research models, AOD-9604 exposure has been associated with modulation of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and matrix metalloproteinases (MMPs). These enzymes and cytokines play central roles in cartilage degradation and joint matrix turnover. If AOD-9604 can suppress MMP activity or reduce inflammatory cytokine signaling in joint tissue, that would represent a plausible chondroprotective mechanism.

The proposed mechanism is distinct from AOD-9604's lipolytic pathway. Heffernan et al. showed definitively that AOD-9604 does not bind the growth hormone receptor.^[3] Whatever cartilage effects exist appear to operate through growth factor signaling pathways that do not require the classical GH/IGF-1 axis. This is relevant because full-length growth hormone, while it does promote cartilage matrix production, also carries metabolic side effects (hyperglycemia, insulin resistance, IGF-1 elevation) that make it unsuitable for long-term joint therapy. If AOD-9604 achieves cartilage benefits without those side effects, it would represent a meaningful separation of therapeutic activities.

However, the in vitro evidence has not been published in peer-reviewed form with the same rigor as the Kwon and Park animal trial. Much of it appears in secondary literature and review articles rather than as standalone primary research publications. This matters when evaluating the strength of the evidence base.

AOD-9604 in the Context of Orthopaedic Peptide Research

A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons (JAAOS) examined the state of therapeutic peptide research across orthopaedics, covering AOD-9604 alongside peptides like BPC-157 and TB-500.^[6] The review classified AOD-9604 among growth hormone secretagogues that "activate IGF-1 signaling and satellite cell repair," though this characterization is debated given evidence that AOD-9604 specifically does not activate IGF-1 signaling.

The review's broader conclusion applies directly to AOD-9604's cartilage claims: the current orthopaedic peptide literature is "dominated by animal models, small prospective cohorts, and case series, with very limited RCTs." For AOD-9604 specifically, there are no prospective cohorts or case series, only the single rabbit study and in vitro work. The review emphasized that "any clinical use should be framed as exploratory and hypothesis generating rather than standard of care."^[6]

This evidence gap is not unique to AOD-9604. Related GH secretagogue peptides like GHRP-2 have shown anti-inflammatory effects in arthritic animal models, with Granado et al. demonstrating reduced arthritis scores and IL-6 suppression in rats.^[7] The broader pattern across peptide joint research is consistent: promising preclinical signals without clinical confirmation. For a broader view of peptide approaches to joint disease, see our article on anti-inflammatory peptides for joint disease.

Why the Combination with Hyaluronic Acid Matters

The Kwon and Park study's most notable finding was not that AOD-9604 alone helped cartilage, but that the combination of AOD-9604 with hyaluronic acid outperformed either treatment individually.^[5] Hyaluronic acid is already an established (though debated) intra-articular treatment for knee osteoarthritis, with multiple systematic reviews examining its efficacy.

HA injections provide viscosupplementation, improving joint lubrication and shock absorption. If AOD-9604 adds a separate chondroprotective or anti-inflammatory mechanism, the combination could theoretically address both the mechanical and biological aspects of cartilage degeneration. The synergy observed in the rabbit model supports this dual-mechanism hypothesis.

The practical relevance is that HA injections are already widely used clinically, which means adding AOD-9604 to existing HA protocols would represent an incremental step rather than a completely novel therapeutic approach. This could simplify the path to clinical testing if researchers chose to pursue it. To date, no such clinical trial has been initiated.

The Regulatory Landscape

AOD-9604 has an unusual regulatory history. After the obesity program failed, the peptide received GRAS (Generally Recognized As Safe) status from the FDA in 2021 as a food ingredient, based on its safety profile across six human clinical trials involving over 900 participants. The GRAS designation applies only to oral consumption as a food ingredient and has no bearing on intra-articular injection for joint indications.

In Australia, AOD-9604 is classified as a Schedule 4 (prescription-only) substance. Claims that the Australian TGA "approved" AOD-9604 for cartilage repair are misleading. The compound can be prescribed through compounding pharmacies under a doctor's supervision, but it has not received formal marketing approval as a pharmaceutical product for any indication from the TGA or any other regulatory body worldwide. For more on AOD-9604's regulatory status, see our article on AOD-9604's FDA GRAS status.

What Would Be Needed to Validate Cartilage Claims

Moving AOD-9604 from "interesting preclinical observation" to "validated cartilage therapy" would require a defined research program:

1. Dose-response studies in validated OA models. The rabbit study used a single dose (0.25 mg). Multiple doses across different animal OA models (spontaneous, surgical, and chemically induced) would establish whether the effect is robust and reproducible.

2. Mechanistic studies with molecular endpoints. Measuring specific markers of cartilage metabolism (aggrecan, type II collagen, MMP-13, ADAMTS-5, IL-6, TNF-alpha) in treated versus untreated tissue would clarify the biological mechanism.

3. Head-to-head comparisons with established treatments. Comparing AOD-9604 against corticosteroid injections, platelet-rich plasma, or other emerging joint therapies would establish relative efficacy.

4. Human clinical trials with imaging endpoints. MRI-based cartilage thickness measurements, WOMAC pain scores, and functional outcomes in human OA patients would be the definitive test. No such trial is currently registered.

Without this progression, AOD-9604's cartilage effects remain a single-study observation in a rabbit model, supported by unpublished in vitro data. That is not evidence of inefficacy. It is evidence of insufficient investigation. The distinction matters. For additional context on how collagen peptides have progressed through clinical validation for joint endpoints, the comparison illustrates what a more mature evidence base looks like.

The Disconnect Between Marketing and Evidence

AOD-9604 is widely marketed online for joint health, often with language suggesting clinical validation that does not exist. Phrases like "promotes cartilage repair" and "joint regeneration" appear on compounding pharmacy and peptide vendor sites without qualifying that the evidence comes from a single rabbit study. The gap between marketing claims and published evidence is substantial.

The peptide's GRAS status is sometimes cited as evidence of safety for intra-articular injection, but GRAS applies exclusively to oral consumption as a food ingredient. Route of administration matters in pharmacology; the safety profile of a substance taken orally does not automatically extend to direct injection into a joint capsule.

The Bottom Line

AOD-9604 showed cartilage-protective effects in one published rabbit OA study and in vitro chondrocyte experiments, with the combination of AOD-9604 and hyaluronic acid outperforming either treatment alone. The peptide does not bind the growth hormone receptor and does not raise IGF-1 or glucose levels, which would be advantageous for long-term joint therapy if the cartilage effects prove real in humans. No human clinical trial has tested AOD-9604 for any cartilage or joint endpoint, and the gap between the preclinical signal and clinical validation remains unbridged.

Frequently Asked Questions

Does AOD-9604 help with cartilage repair?

In one published rabbit study, intra-articular AOD-9604 injections reduced cartilage degeneration scores compared to saline controls, with the combination of AOD-9604 and hyaluronic acid producing the best outcomes. In vitro research suggests the peptide stimulates proteoglycan and collagen synthesis in cartilage cells. No human clinical trial has tested AOD-9604 for cartilage repair, so the evidence remains preclinical.

Is AOD-9604 FDA approved for joint pain?

AOD-9604 is not FDA approved for joint pain or any medical indication. It received GRAS (Generally Recognized As Safe) status in 2021 as a food ingredient, based on safety data from obesity clinical trials. The GRAS designation applies only to oral consumption as a food ingredient and does not authorize its use for joint treatment.

How is AOD-9604 different from growth hormone for joints?

Unlike full-length human growth hormone, AOD-9604 does not bind the growth hormone receptor, does not raise IGF-1 levels, and does not impair insulin sensitivity or raise blood glucose. Heffernan et al. (2001) demonstrated this receptor independence in Endocrinology. If AOD-9604 provides cartilage benefits, it would do so without growth hormone's metabolic side effects.

What did the AOD-9604 rabbit study find?

Kwon and Park (2015) induced osteoarthritis in 32 rabbits and compared four treatment groups over 8 weeks. The combination of AOD-9604 (0.25 mg) with hyaluronic acid (6 mg) produced the lowest cartilage degeneration scores on both gross morphological and histopathological assessments, and the shortest lameness period of any group.

Can AOD-9604 be injected into joints?

In the published rabbit study, AOD-9604 was administered via ultrasound-guided intra-articular injection. In clinical practice, some compounding pharmacies prepare AOD-9604 for injection under a doctor's prescription. No regulatory authority has approved AOD-9604 for intra-articular use, and no human safety data exists specifically for this route at joint-targeted doses.

What peptides are being researched for osteoarthritis?

Multiple peptides are under investigation for osteoarthritis, including AOD-9604, BPC-157, TB-500 (thymosin beta-4), pentosan polysulfate, and collagen-derived peptides. A 2026 JAAOS review by Rahman et al. found that the orthopaedic peptide literature is dominated by animal models with very limited randomized controlled trials across all these compounds.